Clinical trial
Exisulind Versus Placebo After Surgical Removal of the Prostate
NCT00166426 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00166426 |
|---|---|
| Title | Exisulind Versus Placebo After Surgical Removal of the Prostate |
| Official title | Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Exisulind |
| Enrollment | 240 |
| Start date | Feb 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 16, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: